Previous 10 | Next 10 |
LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a confer...
Partnership between LumiraDx and Axonlab will allow Axonlab to sell the unique LumiraDx Point of Care testing solution and give LumiraDx the ability to expand the reach of the LumiraDx Platform and tests. The agreement combines Axonlab's strong, direct and established commercial network wit...
LONDON, June 30, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a leading innovator in diagnostic technologies, today announced the submission of its first 510(k) application to the U.S. Food and Drug Administration (FDA) for the clearance of its ground-breaking 5-minute COVID Ultra Te...
2023-06-22 06:00:00 ET 3 Tips for Making Money With Penny Stocks No Matter the Market Condition Penny stocks, often overlooked in the financial realm, present exciting opportunities for savvy investors. These low-priced securities, typically valued less than $5 a share, possess a potent...
2023-06-20 23:00:34 ET Penny stocks are shares of companies that trade for less than $5. That’s the standard definition of the term, but most traders who’re familiar with the idea generally focus on cheaper stocks. In this article, we look at some of the lowest-priced stocks i...
LumiraDx SARS-CoV-2 Ag Ultra & SARS-CoV-2 Ag & RSV tests have been successfully validated by the Medicines and Healthcare products Regulatory Agency (MHRA) under the Coronavirus Test Device Approvals (CTDA) process. These assays join the LumiraDx SARS-CoV-2 Ag and SARS-CoV-2 Ag &a...
2023-05-16 14:30:02 ET LumiraDx Limited (LMDX) Q1 2023 Earnings Conference Call May 16, 2023 08:30 AM ET Company Participants Melissa Garcia - Vice President Corporate Counsel Ron Zwanziger - Chairman & Chief Executive Officer Dorian LeBlanc - Chief Financial...
2023-05-16 07:55:04 ET LumiraDx press release ( NASDAQ: LMDX ): Q1 Non-GAAP EPS of -$0.13 in-line. Revenue of $22.17M (-82.5% Y/Y) beats by $2.74M . For further details see: LumiraDx Non-GAAP EPS of -$0.13 in-line, revenue of $22.17M beats by $2.74M
LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First quarter 2023 revenues of $22.2 million. Cost reduction programs impl...
LONDON, May 09, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results on Tuesday, May 16 t h , 2023. On the day of the release, LumiraDx will host a...